浙江大洋生物科技集团股份有限公司 2021 年第三季度报告 证券代码：003017 证券简称：大洋生物 公告编号：2021-087 浙江大洋生物科技集团股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中 财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | | 本报告期 | 本报告期比上年同期增减 | 年初至报告期末 | 年初至报告期末比上年 同期增减 | | --- | --- | --- | --- | --- | --- | | 营业收入（元） | | 181,814,312.81 | 4.98% | 567,734,774.83 | 14 ...

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 385,920,462.02, representing a 19.67% increase compared to CNY 322,491,055.73 in the same period last year[19]. - The net profit attributable to shareholders of the listed company was CNY 52,534,375.83, a slight increase of 1.65% from CNY 51,680,438.56 year-on-year[19]. - The net profit after deducting non-recurring gains and losses decreased by 12.53% to CNY 43,494,392.58 from CNY 49,725,107.46 in the previous year[19]. - Basic and diluted earnings per share decreased by 23.48% to CNY 0.88 from CNY 1.15 in the previous year[19]. - The weighted average return on net assets fell to 5.37%, down from 9.95% in the same period last year, a decrease of 4.58%[19]. - The gross margin for the first half of 2021 was reported at 45%, a slight increase from 42% in the same period last year[90]. - The company reported a total revenue of 1.5 billion RMB for the first half of 2021, representing a year-over-year increase of 20%[97]. Cash Flow and Assets - The net cash flow from operating activities significantly dropped by 77.03% to CNY 17,447,589.95, down from CNY 75,972,911.39 in the same period last year[19]. - The company's cash flow from operating activities decreased by 77.03% to ¥17,447,589.95, primarily due to rising raw material prices and increased inventory procurement[43]. - The total assets at the end of the reporting period were CNY 1,258,913,654.84, an increase of 2.45% from CNY 1,228,800,981.37 at the end of the previous year[19]. - The company's cash and cash equivalents were CNY 56,329,966.13, down from CNY 69,359,845.27, reflecting a decrease of approximately 18.5%[144]. - The company reported a significant increase in inventory, which rose to ¥113,348,908.84, representing 9.00% of total assets, due to expanded production scale and increased stockpiling[52]. Operational Highlights - The sales volume of potassium carbonate increased by 33.44% year-on-year due to market demand, while the sales price also saw a slight rise[27]. - Operating costs rose by 27.44% year-on-year, influenced by the increase in coal and raw material prices[41]. - The company has a comprehensive annual production capacity of 77,000 tons for potassium carbonate, maintaining a leading position in the domestic market[28]. - The company is implementing a project to produce 25,000 tons of potassium carbonate and 15,000 tons of potassium bicarbonate, further consolidating its market position[28]. Environmental Compliance - The company has established a wastewater treatment facility with a capacity of 1500m³/day, adhering to the GB21904-2008 standards for chemical synthesis pharmaceutical wastewater, achieving compliance with the strictest discharge limits[78]. - The company reported a total wastewater discharge of 4.2 tons in the first half of the year, with an annual limit of 48 tons, indicating no exceedance of discharge standards[77]. - The company has implemented a closed-loop water usage system at its production base, resulting in zero wastewater discharge from the process[79]. - The company has a waste gas treatment system that meets the ultra-low emission limits, with real-time monitoring of pollutants such as sulfur dioxide and nitrogen oxides[79]. - The company has established a regular leak detection and repair system for VOCs emissions, ensuring compliance with environmental standards[79]. Strategic Initiatives - The company plans to enhance its brand influence and customer relationships to maintain its leading position in the industry[68]. - The company aims to optimize its product structure and expand its market share in fine chemical products, particularly fluorinated fine chemicals[68]. - The company is investing 100 million CNY in R&D for new technologies aimed at enhancing product efficiency[90]. - Market expansion plans include entering two new provinces, expected to increase market share by 5%[91]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million CNY allocated for potential deals[92]. Shareholder and Governance Matters - The company plans not to distribute cash dividends or issue bonus shares[5]. - The company has a share lock-up period of 36 months for major shareholders, which is currently being adhered to[86]. - The company reported a normal performance of share transfer restrictions, with a commitment to not transfer shares within one year of listing[87]. - The company is in compliance with the regulations set by the China Securities Regulatory Commission regarding share reduction[89]. - The company has committed to a stock repurchase plan to stabilize its stock price if the closing price falls below the latest audited net asset value per share for 20 consecutive trading days[98]. Financial Reporting and Compliance - The semi-annual financial report was not audited[108]. - The company has been compliant with the accounting standards, ensuring that financial statements accurately reflect its financial position and operating results[188]. - The company has not identified any significant issues that would raise doubts about its ability to continue as a going concern over the next 12 months[187]. - The company’s financial reporting period is from January 1 to December 31, with the current report covering January 1 to June 30, 2021[189].

证券代码：003017 证券简称：大洋生物 浙江大洋生物科技集团股份有限公司投资者关系活动记录表 编号：2021-002 | --- | --- | --- | |----------------|------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Group 1: Company Performance and Financials - The company reported a production capacity of 77,000 tons for potassium carbonate by the end of 2020, maintaining a leading position in the light potassium carbonate sector [2] - The planned production for 2021 includes 88,000 tons of potassium carbonate, 500 tons of ammonium chloride, and 1,600 tons of fluorine fine chemicals [2] - The company experienced a significant increase in production costs due to rising raw material prices, particularly coal, impacting profit margins [4][5] Group 2: Market Position and Competition - The company is one of only two producers of ammonium chloride globally, with a production capacity of 600 tons [2] - The domestic potassium carbonate market has an annual production capacity of 220,000 tons, with a consumption of 171,800 tons in 2019 [6] - The company has established partnerships with over 20 domestic and international listed companies, enhancing its brand and market presence [7] Group 3: Investor Relations and Communication - The company emphasizes the importance of investor relations and actively participates in investor reception activities [1] - There is a commitment to improving communication with investors, including timely updates on company news and performance [7] - The management acknowledges the need for more transparent and meaningful responses to investor inquiries to avoid misunderstandings [7]

证券代码：003017 股票简称：大洋生物 公告编号：2021-060 浙江大洋生物科技集团股份有限公司 关于举行 2020 年度网上业绩说明会暨参加浙江辖区上市公司 投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 浙江大洋生物科技集团股份有限公司（以下简称"公司"）2020 年年度报 告已于 2021 年 4 月 26 日披露，为进一步加强公司与投资者的沟通交流，让广大 投资者能进一步了解公司 2020 年经营情况，使广大投资者能更深入全面的了解 公司未来发展战略，公司将于 2021 年 5 月 13 日（星期四）在"全景·路演天下" 网站（http://rs.p5w.net）举办 2020 年度业绩说明会。同时，公司将参加由浙 江上市公司协会与深圳市全景网络有限公司共同举办的浙江辖区上市公司投资 者网上集体接待日主题活动。本次业绩说明会和投资者网上集体接待日主题活动 将采用网络在线交流方式进行，投资者可以登录"全景·路演天下"网站参与交 流。 网上业绩说明会时间为 2021 年 5 月 13 日（星期四）下午 15:00 至 ...

浙江大洋生物科技集团股份有限公司 2021 年第一季度报告全文 浙江大洋生物科技集团股份有限公司 2021 年第一季度报告 2021 年 04 月 1 浙江大洋生物科技集团股份有限公司 2021 年第一季度报告全文 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 176,677,783.46 | 136,004,982.75 | 29.91% | | 归属于上市公司股东的净利润（元） | 25,212,102.44 | 20,880,078.78 | 20.75% | | 归属于上市公司股东的扣除非经常性损 益的净利润（元） | 20,143,474.18 | 19,959,569.19 | 0.92% | | 经营活动产生的现金流量净额（元） | 2,883,434.02 | -1,257,822.50 | 329.24% | | 基本每股收益（元/股） | 0.42 | 0.46 | -8.70% | | 稀释每股收益（元/股） | 0.42 | 0.46 | -8.70% | | 加权平均净资产收益率 | 2.6 ...

Financial Performance - The company's operating revenue for 2020 was ¥678,335,140.62, representing a 9.10% increase from ¥621,750,703.44 in 2019[14]. - The net profit attributable to shareholders for 2020 was ¥91,606,026.29, up 15.23% from ¥79,497,183.59 in 2019[14]. - The net profit after deducting non-recurring gains and losses was ¥85,425,535.40, a 13.46% increase compared to ¥75,288,801.80 in 2019[14]. - The basic earnings per share for 2020 was ¥1.93, reflecting a 9.04% increase from ¥1.77 in 2019[14]. - The total assets at the end of 2020 reached ¥1,228,800,981.37, a significant increase of 90.33% from ¥645,600,400.25 at the end of 2019[14]. - The net assets attributable to shareholders increased by 92.36% to ¥958,130,257.80 from ¥498,086,399.85 in 2019[14]. - The net cash flow from operating activities was ¥112,488,116.30, showing a slight decrease of 0.53% from ¥113,092,957.86 in 2019[14]. - The weighted average return on equity for 2020 was 15.20%, down from 16.54% in 2019[14]. - The company achieved operating revenue of 678.34 million yuan, a year-on-year increase of 9.10%[52]. - The net profit attributable to shareholders reached 91.61 million yuan, reflecting a growth of 15.23% compared to the previous year[52]. - Total assets at year-end amounted to 1.23 billion yuan, an increase of 90.33% from the beginning of the year[52]. - The company’s capital reserve increased by 187.32% to 563.99 million yuan due to the premium from the initial public offering[40]. - The company’s asset-liability ratio improved to 22.03%, down from 22.85% the previous year, indicating enhanced short-term solvency[52]. Market and Product Development - The company is actively developing new products, including a project to produce 25,000 tons of potassium carbonate and 15,000 tons of potassium bicarbonate annually, expected to alleviate capacity constraints[25]. - The market for potassium bicarbonate is projected to grow due to increasing health awareness in the food industry, with the company holding a significant market share due to cost advantages in production[25]. - The company has established a strong position in the animal health market with its product, Amprolium Hydrochloride, which has received certifications from the EU and FDA, allowing access to high-end markets[26]. - The production of fluorinated fine chemicals, specifically 2-chloro-6-fluorobenzaldehyde, has seen increased demand due to the global rise in antibiotic needs during the COVID-19 pandemic[27]. - The company’s annual production capacity for potassium carbonate and potassium bicarbonate is 77,000 tons, leading in both capacity and output in the domestic market[31]. - The company has established a long-term stable relationship with major raw material suppliers, ensuring a sufficient and stable supply of key materials[36]. - The company has been recognized for its technological innovation and advanced production processes, establishing itself as a leading enterprise in the potassium carbonate and bicarbonate industry[31]. - The company is focusing on developing high-end chemical products and enhancing its production capabilities in response to national policies promoting green and sustainable development[105]. Sales and Revenue - The company’s inorganic salt products accounted for 67.15% of total revenue, with potassium carbonate and ammonium bicarbonate contributing 62.88%[62]. - Domestic sales reached ¥525,562,224.08, making up 77.48% of total revenue, with a growth of 10.59% year-on-year[70]. - The company achieved an overseas revenue of ¥152,772,916.54, which is 22.52% of total revenue, reflecting a 4.26% increase from the previous year[68]. - The revenue from self-operated product exports was ¥117,726,900, an increase of 13.45% compared to the previous year[71]. - The company is actively expanding its overseas market presence to increase market share and improve service levels[71]. Research and Development - Research and development expenses totaled 22.33 million yuan, with 8 projects completed and 2 new patents granted during the year[55]. - The company has five invention patents and two non-patented technologies for potassium carbonate production, emphasizing low energy consumption and high production efficiency[63]. - The company is committed to increasing R&D investment to support high-quality development and extend its product chain in line with its strategic planning[114]. Corporate Governance and Compliance - The company has fulfilled all commitments made by actual controllers, shareholders, related parties, and acquirers during the reporting period[126]. - The company completed the business change registration within three months after the stock issuance[127]. - The company has committed to ensuring that the electronic and written documents submitted during the IPO process are consistent[127]. - The company will comply with regulations regarding share reduction as stipulated by the China Securities Regulatory Commission[128]. - The company has made commitments regarding the consistency of public disclosures with the final documents approved by the regulatory authority[127]. Social Responsibility and Environmental Impact - The company donated RMB 500,000 to the local charity during the pandemic, showcasing its commitment to social responsibility[60]. - The company has a wastewater treatment facility with a capacity of 1500m³/day, adhering to the GB21904-2008 standards for chemical synthesis pharmaceutical wastewater[187]. - The company reported a total wastewater discharge of 10.4 tons/year, which is below the permitted limit of 48 tons/year[186]. - The company’s air emissions from the boiler are compliant with the emission standards, with sulfur dioxide emissions recorded at 2.35 tons/year against a limit of 10.55 tons/year[186]. - The company has implemented a VOCs treatment system that includes a three-stage condensation and RTO system, ensuring compliance with the DB33/2015-2016 standards for air pollutants[189]. - The company is committed to continuous environmental investment and innovation, focusing on reducing waste emissions and promoting green development[186]. Future Outlook - The company plans to distribute a cash dividend of RMB 6.00 per 10 shares, totaling RMB 36,000,000.00 for the 2020 fiscal year[121]. - The company has set a performance guidance for 2021, targeting a revenue growth of 18% and a net profit increase of 12%[134]. - The company is actively exploring energy-saving and emission-reduction technologies to comply with increasing environmental standards[116]. - The company aims to enhance brand recognition and market positioning through effective marketing strategies and by improving product market share[113].

浙江大洋生物科技集团股份有限公司 2020 年第三季度报告全文 浙江大洋生物科技集团股份有限公司 2020 年第三季度报告 2020 年 10 月 1 浙江大洋生物科技集团股份有限公司 2020 年第三季度报告全文 第一节重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人陈阳贵、主管会计工作负责人陈旭君及会计机构负责人(会计主 管人员)金丽娟声明：保证季度报告中财务报表的真实、准确、完整。 2 浙江大洋生物科技集团股份有限公司 2020 年第三季度报告全文 第二节公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 779,051,839.31 | | 645,600,400.25 | 20.67% | | 归属于上市公司股东的净资产 | 5 ...